SlideShare a Scribd company logo
1 of 34
Dugorocni rezultati lecenja koronarne in-stent restenoze balonom sa secivima Z. Mehmedbegovic, V. Dedovic, G. Stankovic, V. Vukcevic, D. Orlic,  S. Stojkovic, B. Beleslin,  A. Aranđelovic, M. Dikic, M. Živkovic, M. Nedeljkovic,   M. Ostojic Klinika za kardiologiju Klinicki Centar Srbije
In-stent restenoza (ISR) Bojenje kolagena Bojenje glatkih misicnih celija  Circulation. 2006;114:1745-1754. Post PTCA (balon) - oko 30-40% N Engl J Med. 1994;331:496–501 Post BMS -  20-30% Post DES -  10-20% Nakon implantacije stenta
5-37% Tretman in stent restenoze i ponovna revaskularizacija (TLR)
Balon sa secivima (BS) B alon sa secivima sadrži 3 ili 4  mikrohirurska seciva longitudinalno  postavljena na njegovoj povrsini i potpuno je  nekomplijantan  ( Barath sa saradnicima 1991 ) Na balonima dijametra od 2 do 3.25 mm montirana su po tri seciva, a na balonima dijametra 3.5 do 4 mm po cetiri seciva Duzina balona sa secivima (Cutting Balloon, Boston Scientific, Natick, MA) iznosi  6, 10 ili 15 mm , a dostupne  su  dimenzije balona od  2 do 4 mm , sa porastom od 0.25 mm. N aduvavanjem balona  seciva se  eksternalizuju  na povrsinu balona U neekspandiranoj formi balona seciva se nalaze  sakrivena – “spakovana” Inflacija balona Secivo
Mehanizam angioplastike  BS  je bifazni: 1. inicijalna  kontrolisana incizija  aterosklerotskog plaka mirkotomskim secivima,  2.  ravnomerna  dilatacija arterije balonom. Prednost:  odsustvo istezanja zida arterije i nekontrolisanog prskanja plaka u tackama najmanjeg otpora, koje su najcesci uzrok disekcija zida krvnog suda. Klinicki racionale: Manja  trauma  krvnog suda # > Manja  inflamatorna reakcija  *   > Manja verovatnoca  restenoze *  Inoue et al. Circulation 1998; 97(25):2511-2518 # Hara et al, A J Cardiol 2002; 89(11):1253-1256 BS - mehanizam, efekat I prednosti
Cilj istrazivanja Primarni cilj : Ucestalost nezeljenih srcanih dogadjaja  MACE* (smrt, infarkt miokarda i  ponovna revaskularizacija lecenog  suzenja (TLR) ) u periodu pracenja kod pacijenata sa ISR  lecenih dilatacijom  BS   vs  B S  +  dodatnim sredstvom (D S ) Sekudarni cilj:  Ucestalost  TLR  ISR lecenih  BS  vs  BS  + DS Identifikacija klinickih/proceduralnih prediktora za TLR * Mayor adverse cardiac events
Studirana populacija  10364  broj PCI Retrospektivn a analiza CardioReport , S al a  za kateterizaciju KCS,  1.1. 2006- 1.1. 2011. godine. 143 bolesnika/167 suzenja Balon sa secivima (BS)   upotrebljen u sklopu PCI procedura 111 bolesnika 129 ISR  BS lecenje In stent restenoza  (ISR) 32 bolesnika BS lecenje De novo suzenja
111 bolesnika 129 ISR  BS lecenje In stent restenoza  (ISR) Studirana populacija  Vs 75 bolesnika 83 ISR  Samo BS GRUPA 1 36 bolesnika 46 ISR  BS + NC balon/BMS/DES  GRUPA 2
BM Stent Dec 2009 Apr 2010 ISR Balon sa secivima Finalni rezultat
Metodologija: Follow-up Fizicki pregled ili telefonski kontakt  sa bolesnikom i  nadležnim kardiologom nakon mesec dana od  procedure, 6  i 12 meseci od procedure i nakon toga sukcesivno svake  n aredne godine. Bolesnicima je radjena kontrolna angiografija  prema  klinickim indikacijama  ( u slucaju ponovne pojave simptoma  i/ili pozitivnog testa opterecenja.
Statisticka analiza Analiticke metode koje s koriscene : Kontinuirane varijable su poredjene  Studentovim t-testom i  analizom varijanse  (ANOVA, sa Bonferoni i Scheffe korekcijom) a  kategorijske  χ2- testom po Pearson-u ,  sa Yates-ovom korekcijom u  (slucaju malog broja slucajeva) Dugorocno preživljavanje bolesnika prikazano je  Kaplan-Meier- ovim krivama preživljavanja.  Log-rank testom  je izvrseno poredjnje  krivih u predefinisanim populacijama bolesnika. Univarijantni i multivarijantni regresioni modeli  primenjeni su radi  ispitivanja moguce znacajne povezanosti neželjenih srcanih  dogadjaja sa pojedinim demografskim, klinickim, angiografskim i  proceduralnim parametrima.
Klinicke karakteristike ispitivane populacije Broj bolesnika 111 Starost, godine (raspon) 58 . 22  8 . 72  (3 5 - 81 ) Muskarci 87 (78.3%) Hipertenzija 63  ( 56 . 8 %) Diabetes mellitus 30  ( 27 . 0 %) Bivsi ili sadasnji pusac 56  ( 51 .4%) Hiperholesterolemija 65  (5 8 . 6 %) Porodicna anamneza za KB 39  ( 35 . 1 %) Prethodni infar k t miokarda 65  (5 8 . 6 %) Prethodni by-pass 6  ( 5 . 4 %) Indikacije za intervenciju Stabilna angina pektoris 85  ( 86 . 6 %) Nestabilna angina pektoris 2 1  ( 1 8 . 9 %) NSTEMI 1  ( 0 . 9 %) STEMI 4   (3.6%)
Klinicke  karakteristike populacije BS  75 pts BS + DS 36 pts Total 111 pts P BS vs BS+DS Starost, godine (raspon) 58.5  8.5 57.8  8.3 58 . 22  8 . 72 0.855 Muskarci 59 (78.7%) 28 (77.8%) 87 (78.3%) 0.55 Hipertenzija 42 (56%) 20 (55.6%) 6 2  ( 5 5 . 8 %) 0.80 Diabetes mellitus 17 (22.6) 12 (33%) 29 (26.1%) 0.22 Bivsi ili sadasnji pusac 39 (52%) 17 (47.3%) 56  ( 51 .4%) 0.09 Hiperholesterolemija 40 (60%) 20 (55.6%) 65  (5 8 . 6 %) 0.94 Porodicna anamneza za KB 24 (32%) 14 (38.4%) 3 8 ( 34 . 2 %) 0.69 Prethodni infar k t miokarda 44 (58.7%) 21 (58.3%) 65  (5 8 . 6 %) 0.55 Prethodni by-pass 4 (5.3%) 2 (5.6%) 6  ( 5 . 4 %) 0.90 Stabilna angina pektoris 53 (70.7%) 32 (88.9%) 85  ( 86 . 6 %) 0.056 Nestabilna angina pektoris 18 (24%) 4 (11.1%) 2 2  ( 1 9 . 8 %) 0.22 NSTEMI 0 (0%) 0 (0%) 0  ( 0 %) NA STEMI 4 (5.3%) 0 (0%) 4   (3.6%) 0.16
PCI  BS  dilatacijom prema broju lezija 15 3 93 Broj bolesnika 111 Broj tretiranih lezija 16.2%
Angiografske karakteristike Broj bolesnika 111 Broj lecenih lezija 167 De-novo  lezija 38 (22.8%) In-stent restenoza 129 (77.2%) Lokalizacija lezije (No lezija/% ukupnog broja):  LAD 68 (40.7%) Cx 34 (20.4%) RCA 58 (34.7%) SVG 2 (1.2%) RI 2 (1.2%) GS 2 (1.2%) Ostijalna 4 (2.4%) Proksimalna 64 (38.3%) Medijalna 59 (35.3%) Distalna 40 (24%)
Angiografske karakteristike tretiranih ISR BS  83  ISR (%) BS + DS 46 ISR (%) Total 129 ISR P BS vs BS+DS LAD 36 (43.3) 21 (55.6) 57(44.2 ) za sve 0.225 RCA 25 (30.) 19 (33.3) 34 (26.4) CX 21 (25.3) 6 (11.1) 27 (20.9) SVG 1 (1.3) 0 (0)  1 (1) Ostijalna 1 (1.3) 2 (4.3) 3 (2) za  sve  0.545 Proksimalna 38 (45.8) 12 (26.1) 50 (38.8) Medijalna 25 (30.1) 20 (43.4) 45 (34.9) Distalna 19 (22.9) 12 (26.1) 21 (24.1)
Angiografske karakteristike tretiranih ISR BS  83 ISR (%) BS + DS 46 ISR (%) Total 129 ISR P BS vs BS+DS Bifurkacija 16 (19.3) 10 (21.7) 26 (20.2) 0.74 Totalna okluzija 2 (2.4) 3 (6.5) 5 (3.9) 0.25 Kompleksna PCI 23 (27.7) 12(26.1) 35 (27.1) 0.85 Komplikacija  1  ( 1.2 ) 1  ( 2.1 )  1 (0.8) 0.18 Disekcija 2 (2.4) 0 (0) 2 (1.6) 0.23 Dijametar krvnog suda <  3mm 28 (33.7%) 9 (18.4%) 37 (28.7) 0.088 Duzina ISR >20mm 26 (31) 15 (32.6) 41 (31.8) 0.88 Rezidualna stenoza >30% 3 (3.6) 0 (0) 3 (2.3) 0.19 Izrazene kalcifikacije 19 (24) 10 (21.7) 29 (22.5) 0.88 Tip ISR Fokalna (<10mm) 46 (55) 16 (34.8) 62 (48.1) za sve 0.075 Difuzna (u stentu) 31 (37.5) 26 (56.5) 57 (44.7) Proliferativna (van stenta) 6 (7.2) 3 (6.5) 9  (7)
60.5 % 12.6% 6.6% 20.4% 101 21 11 34 Definitivan tretman lezija prema tipu sredstva Total broj lezija 167:  De novo 38 + 129 ISR
6 4 . 3% 8.5% 4.7% 22.5% 83 11 6 29 Definitivan tretman ISR prema tipu sredstva 129 ISR 29+6+11= 46 ISR
Uporedne tehnicke karakteristike dilatacije ISR  sa BS 129 ISR BS 83  ISR (Mean ± SD) BS +  Dodatno sredstvo 46  ISR  (Mean ± SD) p B S  dijametar (mm) 3.017 ± .38714 3.00 ±  .32183 N s BS  duzina (mm) 10.70 ± 2.017 12.11 ±  3.671 0.008 BS  pritisak (atm) 12.78 ± 2.683 12.65 ± 3.02 N s BS  No inflacija 1.45 ± 1.044 1.13 ± 0.40 <0.001
Primarni cilj: ucestalost MACE-a u dugorocnom pracenju  Klinicki follow-up je urađen u  91,9%  pacijenata   prosecne dužine  21,6+/-16,7   m es eci A ngiografsku   kontrolu imalo ukupno  43  pacijenta  (38,7%; 43/111). Total: 111 pts B S 75 pts   No (%) BS +  DS 36 pts   No (%) p Smrt   Srcana  0 (0%)   1 (2.8%) Nesrcana  0 (0%)  1 (2.8%) 0.194 Infarkt miokarda 1 (1.3%) 1 (2.8%) 0.592 TLR 14 (18.7%) 8 (22.2%) 0.438 MACE total 26/111 (23.4%) 15 (20.0%) 11 (30.5%) 0.219
Kaplan-Meier kriva prezivljavanja bez MACE-a Log Rank (Mantel-Cox) p=0.128 B S Dodatno sredstvo Total:111 pts
18 . 6% 14 / 75 22 . 2% 8 / 36 Sekundarni  cilj:  ucestalost TLR u dugorocnom pracenju prema broju pacijenata  Total: 111 pts p=0.438 % Total Re PCI ISR = 19,8% pts
1 6.9% 14 / 83 1 9 . 5% 9 / 46 Sekundarni  cilj:  ucestalost TLR u dugorocnom pracenju prema broju tretiranih ISR  Total broj: 129 ISR p=0.701 % Total Re PCI ISR = 17,8% lezija
Kaplan-Meier kriva prezivljavanja bez TLR Log Rank (Mantel-Cox) p=0.505 CB Dodatno sredstvo Total:129 ISR
16.8% 0% 9% 27.6% 83 6 Ucestalost TLR prema tipu sredstva Total broj: 129 ISR 14 69 11 21 8 BS vs NC B  p =0.21 BS vs BMS p=0.99 BS vs DES p=0.31 p za sve >0.05 B ez TLR TLR
Univarijantni prediktori za TLR Demografske karakteristike pacijenata Total: 111 pts TLR  22 pts Bez TLR 89 pts p Starost, godine (raspon) 55.74  ±  9.63 58.74  ±  8.00 0.567 Muskarci 17  (77.2%) 70 (78.6%) 0.888 Hipertenzija 10 (45.4%) 45 (50.6%) 0.089 Diabetes mellitus 7  (31.8%) 20 (22.4%) 0.250 Bivsi ili sadasnji pusac 18 (81.8%) 57 (64%) 0.259 Hiperholesterolemija 14  (63.6%) 44 (49.4%) 0.469 Porodicna anamneza za KB 12  (54.5%) 25  (28%) 0.033 Prethodni infar k t miokarda 11 (50%) 51 (57.3%) 0.242 Prethodni by-pass 2 (9%) 4 (4.5%) 0.470 Nestabilna angina pektoris 8  (36%) 13  (14.6%) 0.039 NSTEMI 1 (4.5%) 0 (%) 0.550 STEMI 2 (9%) 2 (2.3%) 0.138
Univarijantni prediktori za TLR P roceduralne karakteristike dilatacije CB Total: 129  ISR TLR  23 lezije Bez TLR 106 lezija p BS dijametar (mm) 2.954  ± .3 982 3.01 6  ± .3 6 7 5 0.801 BS duzina (mm) 1 1 .0 9  ± 2. 938 11.30 ±  2.245 0.938 BS pritisak (atm) 12.7 6  ± 2. 743 12.13 ± 3.079 0.356 BS No inflacija 1.87 ± 1.517 1. 23  ± . 643 0.002 Odnos  Diam BS / Dijametar kr. suda (DKS) 1: 1.04 1: 1.02 0.893
Univarijantni prediktori za TLR Angiografske karakteristike lokalizacije ISR Total: 129  ISR TLR  23 lezije Bez TLR 106 lezija p LAD 14  (61%) 42  (39.6%) 0.139 RCA 6  (26.1%) 35  (33%) 0.517 Cx 3  (13%) 18  (16.9%) 0.643 SVG 0  (0%) 1  (0.9%) 0.337 O stijalna 1  (4.3%) 2  (1.8%) 0.478 P roksimalna 10  (43.4%) 35  (33%) 0.340 M edijalna 9  (39.1%) 34  (32%) 0.515 D istalna 3  (1342/%) 25  (39.1%) 0.304
Univarijantni prediktori za TLR Karakteristike ISR Total: 129  ISR TLR  23 lezije Bez TLR 106 lezija p Bifurkacija 6  (26.1%) 20 (18.9%) 0.584 Totalna okluzija 3 (13%) 2 (1.9%) 0.019 Kompleksna PCI 11 (47.8%) 24 (22.6%) 0.031 Komplikacija  0 (%) 2 (1.9%) 0.623 Disekcija 0 (%) 2 (1.9%) 0.989 Dijametar krvnog suda <  3mm 9  (39%) 26 (24.6%) 0.225 Duzina ISR >20mm 6 (26.1%) 33 (31.8%) 0.447 Rezidualna stenoza >30% 0 (%) 3 (2.8%) 0.391 Izrazene kalcifikacije 5 (21.7%) 22 (20.7%) 0.904 Tip ISR Fokalna (<10mm) 10 (43.4%) 35 (33%) za sve 0.380 Difuzna (u stentu) 9 (39.1%) 34 (32%) Proliferativna (van stenta) 3 (13%) 25 (23.6%)
Mult ivarijantni prediktori za TLR Total: 129 pts TLR  23 lezije Bez TLR 106 lezija UniVar P MultiVar p Porodicna anamneza za K VB 12  (52.2%) 25  (23.5%) 0.033 0.178 Nestabilna angina pektoris 8  (34.8%) 13  (12.3%) 0.039 0.022 CB No inflacija 1.87 ± 1.517 1. 23  ± . 643 0.002 0.063 Okluzivna ISR 3  (13%) 2  (1.9%) 0.019 0.275 Kompleksna PCI 11  (47.8%) 24  (22.6%) 0.031 0.466
Bare metal stent restenosis is not a benign clinical entity Michael S Chen et al. Am Heart J 2006;151:12602 4 1186 BMS ISR kod 984 bolesnika
Zakljucak ,[object Object],[object Object],[object Object]
Hvala na paznji!

More Related Content

Featured

PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024Neil Kimberley
 
Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)contently
 
How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024Albert Qian
 
Social Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie InsightsSocial Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie InsightsKurio // The Social Media Age(ncy)
 
Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024Search Engine Journal
 
5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summary5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summarySpeakerHub
 
ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd Clark Boyd
 
Getting into the tech field. what next
Getting into the tech field. what next Getting into the tech field. what next
Getting into the tech field. what next Tessa Mero
 
Google's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search IntentGoogle's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search IntentLily Ray
 
Time Management & Productivity - Best Practices
Time Management & Productivity -  Best PracticesTime Management & Productivity -  Best Practices
Time Management & Productivity - Best PracticesVit Horky
 
The six step guide to practical project management
The six step guide to practical project managementThe six step guide to practical project management
The six step guide to practical project managementMindGenius
 
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...RachelPearson36
 
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Applitools
 
12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at Work12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at WorkGetSmarter
 
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...DevGAMM Conference
 
Barbie - Brand Strategy Presentation
Barbie - Brand Strategy PresentationBarbie - Brand Strategy Presentation
Barbie - Brand Strategy PresentationErica Santiago
 

Featured (20)

PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024
 
Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)
 
How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024
 
Social Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie InsightsSocial Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie Insights
 
Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024
 
5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summary5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summary
 
ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd
 
Getting into the tech field. what next
Getting into the tech field. what next Getting into the tech field. what next
Getting into the tech field. what next
 
Google's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search IntentGoogle's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search Intent
 
How to have difficult conversations
How to have difficult conversations How to have difficult conversations
How to have difficult conversations
 
Introduction to Data Science
Introduction to Data ScienceIntroduction to Data Science
Introduction to Data Science
 
Time Management & Productivity - Best Practices
Time Management & Productivity -  Best PracticesTime Management & Productivity -  Best Practices
Time Management & Productivity - Best Practices
 
The six step guide to practical project management
The six step guide to practical project managementThe six step guide to practical project management
The six step guide to practical project management
 
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
 
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
 
12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at Work12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at Work
 
ChatGPT webinar slides
ChatGPT webinar slidesChatGPT webinar slides
ChatGPT webinar slides
 
More than Just Lines on a Map: Best Practices for U.S Bike Routes
More than Just Lines on a Map: Best Practices for U.S Bike RoutesMore than Just Lines on a Map: Best Practices for U.S Bike Routes
More than Just Lines on a Map: Best Practices for U.S Bike Routes
 
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
 
Barbie - Brand Strategy Presentation
Barbie - Brand Strategy PresentationBarbie - Brand Strategy Presentation
Barbie - Brand Strategy Presentation
 

Cutting Balloon

  • 1. Dugorocni rezultati lecenja koronarne in-stent restenoze balonom sa secivima Z. Mehmedbegovic, V. Dedovic, G. Stankovic, V. Vukcevic, D. Orlic, S. Stojkovic, B. Beleslin, A. Aranđelovic, M. Dikic, M. Živkovic, M. Nedeljkovic, M. Ostojic Klinika za kardiologiju Klinicki Centar Srbije
  • 2. In-stent restenoza (ISR) Bojenje kolagena Bojenje glatkih misicnih celija Circulation. 2006;114:1745-1754. Post PTCA (balon) - oko 30-40% N Engl J Med. 1994;331:496–501 Post BMS - 20-30% Post DES - 10-20% Nakon implantacije stenta
  • 3. 5-37% Tretman in stent restenoze i ponovna revaskularizacija (TLR)
  • 4. Balon sa secivima (BS) B alon sa secivima sadrži 3 ili 4 mikrohirurska seciva longitudinalno postavljena na njegovoj povrsini i potpuno je nekomplijantan ( Barath sa saradnicima 1991 ) Na balonima dijametra od 2 do 3.25 mm montirana su po tri seciva, a na balonima dijametra 3.5 do 4 mm po cetiri seciva Duzina balona sa secivima (Cutting Balloon, Boston Scientific, Natick, MA) iznosi 6, 10 ili 15 mm , a dostupne su dimenzije balona od 2 do 4 mm , sa porastom od 0.25 mm. N aduvavanjem balona seciva se eksternalizuju na povrsinu balona U neekspandiranoj formi balona seciva se nalaze sakrivena – “spakovana” Inflacija balona Secivo
  • 5. Mehanizam angioplastike BS je bifazni: 1. inicijalna kontrolisana incizija aterosklerotskog plaka mirkotomskim secivima, 2. ravnomerna dilatacija arterije balonom. Prednost: odsustvo istezanja zida arterije i nekontrolisanog prskanja plaka u tackama najmanjeg otpora, koje su najcesci uzrok disekcija zida krvnog suda. Klinicki racionale: Manja trauma krvnog suda # > Manja inflamatorna reakcija * > Manja verovatnoca restenoze * Inoue et al. Circulation 1998; 97(25):2511-2518 # Hara et al, A J Cardiol 2002; 89(11):1253-1256 BS - mehanizam, efekat I prednosti
  • 6. Cilj istrazivanja Primarni cilj : Ucestalost nezeljenih srcanih dogadjaja MACE* (smrt, infarkt miokarda i ponovna revaskularizacija lecenog suzenja (TLR) ) u periodu pracenja kod pacijenata sa ISR lecenih dilatacijom BS vs B S + dodatnim sredstvom (D S ) Sekudarni cilj: Ucestalost TLR ISR lecenih BS vs BS + DS Identifikacija klinickih/proceduralnih prediktora za TLR * Mayor adverse cardiac events
  • 7. Studirana populacija 10364 broj PCI Retrospektivn a analiza CardioReport , S al a za kateterizaciju KCS, 1.1. 2006- 1.1. 2011. godine. 143 bolesnika/167 suzenja Balon sa secivima (BS) upotrebljen u sklopu PCI procedura 111 bolesnika 129 ISR BS lecenje In stent restenoza (ISR) 32 bolesnika BS lecenje De novo suzenja
  • 8. 111 bolesnika 129 ISR BS lecenje In stent restenoza (ISR) Studirana populacija Vs 75 bolesnika 83 ISR Samo BS GRUPA 1 36 bolesnika 46 ISR BS + NC balon/BMS/DES GRUPA 2
  • 9. BM Stent Dec 2009 Apr 2010 ISR Balon sa secivima Finalni rezultat
  • 10. Metodologija: Follow-up Fizicki pregled ili telefonski kontakt sa bolesnikom i nadležnim kardiologom nakon mesec dana od procedure, 6 i 12 meseci od procedure i nakon toga sukcesivno svake n aredne godine. Bolesnicima je radjena kontrolna angiografija prema klinickim indikacijama ( u slucaju ponovne pojave simptoma i/ili pozitivnog testa opterecenja.
  • 11. Statisticka analiza Analiticke metode koje s koriscene : Kontinuirane varijable su poredjene Studentovim t-testom i analizom varijanse (ANOVA, sa Bonferoni i Scheffe korekcijom) a kategorijske χ2- testom po Pearson-u , sa Yates-ovom korekcijom u (slucaju malog broja slucajeva) Dugorocno preživljavanje bolesnika prikazano je Kaplan-Meier- ovim krivama preživljavanja. Log-rank testom je izvrseno poredjnje krivih u predefinisanim populacijama bolesnika. Univarijantni i multivarijantni regresioni modeli primenjeni su radi ispitivanja moguce znacajne povezanosti neželjenih srcanih dogadjaja sa pojedinim demografskim, klinickim, angiografskim i proceduralnim parametrima.
  • 12. Klinicke karakteristike ispitivane populacije Broj bolesnika 111 Starost, godine (raspon) 58 . 22  8 . 72 (3 5 - 81 ) Muskarci 87 (78.3%) Hipertenzija 63 ( 56 . 8 %) Diabetes mellitus 30 ( 27 . 0 %) Bivsi ili sadasnji pusac 56 ( 51 .4%) Hiperholesterolemija 65 (5 8 . 6 %) Porodicna anamneza za KB 39 ( 35 . 1 %) Prethodni infar k t miokarda 65 (5 8 . 6 %) Prethodni by-pass 6 ( 5 . 4 %) Indikacije za intervenciju Stabilna angina pektoris 85 ( 86 . 6 %) Nestabilna angina pektoris 2 1 ( 1 8 . 9 %) NSTEMI 1 ( 0 . 9 %) STEMI 4 (3.6%)
  • 13. Klinicke karakteristike populacije BS 75 pts BS + DS 36 pts Total 111 pts P BS vs BS+DS Starost, godine (raspon) 58.5  8.5 57.8  8.3 58 . 22  8 . 72 0.855 Muskarci 59 (78.7%) 28 (77.8%) 87 (78.3%) 0.55 Hipertenzija 42 (56%) 20 (55.6%) 6 2 ( 5 5 . 8 %) 0.80 Diabetes mellitus 17 (22.6) 12 (33%) 29 (26.1%) 0.22 Bivsi ili sadasnji pusac 39 (52%) 17 (47.3%) 56 ( 51 .4%) 0.09 Hiperholesterolemija 40 (60%) 20 (55.6%) 65 (5 8 . 6 %) 0.94 Porodicna anamneza za KB 24 (32%) 14 (38.4%) 3 8 ( 34 . 2 %) 0.69 Prethodni infar k t miokarda 44 (58.7%) 21 (58.3%) 65 (5 8 . 6 %) 0.55 Prethodni by-pass 4 (5.3%) 2 (5.6%) 6 ( 5 . 4 %) 0.90 Stabilna angina pektoris 53 (70.7%) 32 (88.9%) 85 ( 86 . 6 %) 0.056 Nestabilna angina pektoris 18 (24%) 4 (11.1%) 2 2 ( 1 9 . 8 %) 0.22 NSTEMI 0 (0%) 0 (0%) 0 ( 0 %) NA STEMI 4 (5.3%) 0 (0%) 4 (3.6%) 0.16
  • 14. PCI BS dilatacijom prema broju lezija 15 3 93 Broj bolesnika 111 Broj tretiranih lezija 16.2%
  • 15. Angiografske karakteristike Broj bolesnika 111 Broj lecenih lezija 167 De-novo lezija 38 (22.8%) In-stent restenoza 129 (77.2%) Lokalizacija lezije (No lezija/% ukupnog broja): LAD 68 (40.7%) Cx 34 (20.4%) RCA 58 (34.7%) SVG 2 (1.2%) RI 2 (1.2%) GS 2 (1.2%) Ostijalna 4 (2.4%) Proksimalna 64 (38.3%) Medijalna 59 (35.3%) Distalna 40 (24%)
  • 16. Angiografske karakteristike tretiranih ISR BS 83 ISR (%) BS + DS 46 ISR (%) Total 129 ISR P BS vs BS+DS LAD 36 (43.3) 21 (55.6) 57(44.2 ) za sve 0.225 RCA 25 (30.) 19 (33.3) 34 (26.4) CX 21 (25.3) 6 (11.1) 27 (20.9) SVG 1 (1.3) 0 (0) 1 (1) Ostijalna 1 (1.3) 2 (4.3) 3 (2) za sve 0.545 Proksimalna 38 (45.8) 12 (26.1) 50 (38.8) Medijalna 25 (30.1) 20 (43.4) 45 (34.9) Distalna 19 (22.9) 12 (26.1) 21 (24.1)
  • 17. Angiografske karakteristike tretiranih ISR BS 83 ISR (%) BS + DS 46 ISR (%) Total 129 ISR P BS vs BS+DS Bifurkacija 16 (19.3) 10 (21.7) 26 (20.2) 0.74 Totalna okluzija 2 (2.4) 3 (6.5) 5 (3.9) 0.25 Kompleksna PCI 23 (27.7) 12(26.1) 35 (27.1) 0.85 Komplikacija 1 ( 1.2 ) 1 ( 2.1 ) 1 (0.8) 0.18 Disekcija 2 (2.4) 0 (0) 2 (1.6) 0.23 Dijametar krvnog suda < 3mm 28 (33.7%) 9 (18.4%) 37 (28.7) 0.088 Duzina ISR >20mm 26 (31) 15 (32.6) 41 (31.8) 0.88 Rezidualna stenoza >30% 3 (3.6) 0 (0) 3 (2.3) 0.19 Izrazene kalcifikacije 19 (24) 10 (21.7) 29 (22.5) 0.88 Tip ISR Fokalna (<10mm) 46 (55) 16 (34.8) 62 (48.1) za sve 0.075 Difuzna (u stentu) 31 (37.5) 26 (56.5) 57 (44.7) Proliferativna (van stenta) 6 (7.2) 3 (6.5) 9 (7)
  • 18. 60.5 % 12.6% 6.6% 20.4% 101 21 11 34 Definitivan tretman lezija prema tipu sredstva Total broj lezija 167: De novo 38 + 129 ISR
  • 19. 6 4 . 3% 8.5% 4.7% 22.5% 83 11 6 29 Definitivan tretman ISR prema tipu sredstva 129 ISR 29+6+11= 46 ISR
  • 20. Uporedne tehnicke karakteristike dilatacije ISR sa BS 129 ISR BS 83 ISR (Mean ± SD) BS + Dodatno sredstvo 46 ISR (Mean ± SD) p B S dijametar (mm) 3.017 ± .38714 3.00 ± .32183 N s BS duzina (mm) 10.70 ± 2.017 12.11 ± 3.671 0.008 BS pritisak (atm) 12.78 ± 2.683 12.65 ± 3.02 N s BS No inflacija 1.45 ± 1.044 1.13 ± 0.40 <0.001
  • 21. Primarni cilj: ucestalost MACE-a u dugorocnom pracenju Klinicki follow-up je urađen u 91,9% pacijenata prosecne dužine 21,6+/-16,7 m es eci A ngiografsku kontrolu imalo ukupno 43 pacijenta (38,7%; 43/111). Total: 111 pts B S 75 pts No (%) BS + DS 36 pts No (%) p Smrt Srcana 0 (0%) 1 (2.8%) Nesrcana 0 (0%) 1 (2.8%) 0.194 Infarkt miokarda 1 (1.3%) 1 (2.8%) 0.592 TLR 14 (18.7%) 8 (22.2%) 0.438 MACE total 26/111 (23.4%) 15 (20.0%) 11 (30.5%) 0.219
  • 22. Kaplan-Meier kriva prezivljavanja bez MACE-a Log Rank (Mantel-Cox) p=0.128 B S Dodatno sredstvo Total:111 pts
  • 23. 18 . 6% 14 / 75 22 . 2% 8 / 36 Sekundarni cilj: ucestalost TLR u dugorocnom pracenju prema broju pacijenata Total: 111 pts p=0.438 % Total Re PCI ISR = 19,8% pts
  • 24. 1 6.9% 14 / 83 1 9 . 5% 9 / 46 Sekundarni cilj: ucestalost TLR u dugorocnom pracenju prema broju tretiranih ISR Total broj: 129 ISR p=0.701 % Total Re PCI ISR = 17,8% lezija
  • 25. Kaplan-Meier kriva prezivljavanja bez TLR Log Rank (Mantel-Cox) p=0.505 CB Dodatno sredstvo Total:129 ISR
  • 26. 16.8% 0% 9% 27.6% 83 6 Ucestalost TLR prema tipu sredstva Total broj: 129 ISR 14 69 11 21 8 BS vs NC B p =0.21 BS vs BMS p=0.99 BS vs DES p=0.31 p za sve >0.05 B ez TLR TLR
  • 27. Univarijantni prediktori za TLR Demografske karakteristike pacijenata Total: 111 pts TLR 22 pts Bez TLR 89 pts p Starost, godine (raspon) 55.74 ± 9.63 58.74 ± 8.00 0.567 Muskarci 17 (77.2%) 70 (78.6%) 0.888 Hipertenzija 10 (45.4%) 45 (50.6%) 0.089 Diabetes mellitus 7 (31.8%) 20 (22.4%) 0.250 Bivsi ili sadasnji pusac 18 (81.8%) 57 (64%) 0.259 Hiperholesterolemija 14 (63.6%) 44 (49.4%) 0.469 Porodicna anamneza za KB 12 (54.5%) 25 (28%) 0.033 Prethodni infar k t miokarda 11 (50%) 51 (57.3%) 0.242 Prethodni by-pass 2 (9%) 4 (4.5%) 0.470 Nestabilna angina pektoris 8 (36%) 13 (14.6%) 0.039 NSTEMI 1 (4.5%) 0 (%) 0.550 STEMI 2 (9%) 2 (2.3%) 0.138
  • 28. Univarijantni prediktori za TLR P roceduralne karakteristike dilatacije CB Total: 129 ISR TLR 23 lezije Bez TLR 106 lezija p BS dijametar (mm) 2.954 ± .3 982 3.01 6 ± .3 6 7 5 0.801 BS duzina (mm) 1 1 .0 9 ± 2. 938 11.30 ± 2.245 0.938 BS pritisak (atm) 12.7 6 ± 2. 743 12.13 ± 3.079 0.356 BS No inflacija 1.87 ± 1.517 1. 23 ± . 643 0.002 Odnos Diam BS / Dijametar kr. suda (DKS) 1: 1.04 1: 1.02 0.893
  • 29. Univarijantni prediktori za TLR Angiografske karakteristike lokalizacije ISR Total: 129 ISR TLR 23 lezije Bez TLR 106 lezija p LAD 14 (61%) 42 (39.6%) 0.139 RCA 6 (26.1%) 35 (33%) 0.517 Cx 3 (13%) 18 (16.9%) 0.643 SVG 0 (0%) 1 (0.9%) 0.337 O stijalna 1 (4.3%) 2 (1.8%) 0.478 P roksimalna 10 (43.4%) 35 (33%) 0.340 M edijalna 9 (39.1%) 34 (32%) 0.515 D istalna 3 (1342/%) 25 (39.1%) 0.304
  • 30. Univarijantni prediktori za TLR Karakteristike ISR Total: 129 ISR TLR 23 lezije Bez TLR 106 lezija p Bifurkacija 6 (26.1%) 20 (18.9%) 0.584 Totalna okluzija 3 (13%) 2 (1.9%) 0.019 Kompleksna PCI 11 (47.8%) 24 (22.6%) 0.031 Komplikacija 0 (%) 2 (1.9%) 0.623 Disekcija 0 (%) 2 (1.9%) 0.989 Dijametar krvnog suda < 3mm 9 (39%) 26 (24.6%) 0.225 Duzina ISR >20mm 6 (26.1%) 33 (31.8%) 0.447 Rezidualna stenoza >30% 0 (%) 3 (2.8%) 0.391 Izrazene kalcifikacije 5 (21.7%) 22 (20.7%) 0.904 Tip ISR Fokalna (<10mm) 10 (43.4%) 35 (33%) za sve 0.380 Difuzna (u stentu) 9 (39.1%) 34 (32%) Proliferativna (van stenta) 3 (13%) 25 (23.6%)
  • 31. Mult ivarijantni prediktori za TLR Total: 129 pts TLR 23 lezije Bez TLR 106 lezija UniVar P MultiVar p Porodicna anamneza za K VB 12 (52.2%) 25 (23.5%) 0.033 0.178 Nestabilna angina pektoris 8 (34.8%) 13 (12.3%) 0.039 0.022 CB No inflacija 1.87 ± 1.517 1. 23 ± . 643 0.002 0.063 Okluzivna ISR 3 (13%) 2 (1.9%) 0.019 0.275 Kompleksna PCI 11 (47.8%) 24 (22.6%) 0.031 0.466
  • 32. Bare metal stent restenosis is not a benign clinical entity Michael S Chen et al. Am Heart J 2006;151:12602 4 1186 BMS ISR kod 984 bolesnika
  • 33.

Editor's Notes

  1. Sto je razumljivo ako uzmemo u obzir da su tehnicki zahtevnije i rezistentnije lezije na dilataciju sklonije ISR.